The combination of aggressive hydration and rectal non-steroidal anti-1 inflammatory drugs is not superior to rectal non-steroidal anti-inflammatory 2 drugs alone in the prevention of pancreatitis after endoscopic retrograde 3 cholangiopancreatography: a systematic review and meta-analysis 4 5 Xiang Cheng^{1,2†}, Feixiang Yang^{2†}, Xingxin Yang³, Ning Zhang², Xiaoming Li^{3*}, Bo Chen^{1*} 6 7 8 ¹ Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. 9 ² First School of Clinical Medicine, Anhui Medical University, Hefei 230032, China. 10 ³ Department of Medical Psychology, School of Mental Health and Psychological Sciences, Anhui 11 12 Medical University, Hefei 230032, China. 13 [†] These authors contributed equally to this work. 14 15 * Correspondence: 16 17 Bo Chen chenbo@ahmu.edu.cn 18 Xiaoming Li 19

psyxiaoming@126.com 20

21 Abstract

22 Background: endoscopic retrograde cholangiopancreatography (ERCP) can lead to many high-risk 23 complications, of which acute pancreatitis is the most prevalent and serious one. Whether patients who

receive prophylactic rectal non-steroidal anti-inflammatory drugs (NSAIDs) need to be combined with 24

25 aggressive hydration remains controversial.

Aim: The study was performed to determine whether there is collaborative facilitation between rectal 26 27 NSAIDs and aggressive hydration in preventing post-ERCP pancreatitis (PEP).

Methods: We searched all eligible studies on the preventive effects of active rehydration and NSAIDs 28

on PEP from multiple databases including ClinicalTrials, PubMed, CQVIP, Embase, Web of Science, 29

- CNKI, Cochrane Library, and Wanfang Data. We performed a meta-analysis of the data related to the 30
- 31 incidence of PEP as well as the serious cases including the incidence of severe PEP and mortality.

Results: This meta-analysis included three published studies of randomized controlled trials with 1110 32

- 33 patients. Our results showed that additional aggressive hydration was not significantly effective for the
- 34 prevention of PEP in patients who were already receiving rectal NSAIDs (odds ratio [OR], 0.43; 95%

35 confidence interval [CI], 0.12-1.57; P=0.20). With regard to the prevention of serious cases, compared

- with rectal NSAIDs alone, aggressive fluid hydration combined with rectal NSAIDs did not reduce the 36
- morbidity of severe PEP (OR, 0.32; 95% CI, 0.10-1.08; P=0.07), nor did it reduce overall mortality (OR, 37
- 38 0.81; 95% CI, 0.28-2.36; P=0.70).
- 39 Conclusion: Aggressive perioperative hydration combined with rectal NSAIDs was not superior to rectal
- 40 NSAIDs along in the prevention of PEP.
- 41

42

Keywords: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Retrograde; Fluid Therapy; Meta-Analysis; Systematic Review 43

Introduction 44

45 Endoscopic retrograde cholangiopancreatography (ERCP) is conducted to evaluate the pathological 46 changes in bile duct, pancreatic duct, and hepatopancreatic ampullae, such as stones, tumors, and 47 inflammation [1]. The improvement of endoscopic technology advances the application of ERCP in the 48 diagnosis and management of pancreatic and biliary tract diseases, making ERCP a major diagnostic and therapeutic intervention for biliopancreatic lesions [2]. Post-ERCP pancreatitis (PEP) is the most 49 50 prevalent and serious ERCP-associated complication, with an incidence that ranges between 3% and 5% 51 in low-risk patients and as high as 15% in high-risk patients [1-4]. ERCP induces pancreatic injury and 52 inflammation in two main mechanisms: mechanical damage from instrument handling and hydrostatic 53 compression damage from contrast media [5, 6]. There are many ERCP procedures involving prolonged instrument operation of the pancreatic duct, such as long-term or repeated pancreatic intubation, which 54 55 can cause direct injury to the pancreatic duct or ampulla. In addition, some procedures operated by an 56 electric knife can result in mechanical and thermal injury, subsequently lead to secondary trypsin injury after reactive edema and obstruction of the pancreatic duct [5]. The pancreatic injury induced by contrast 57 58 mainly includes hydrostatic compression damaged by overuse of contrast or chemical or allergic damage 59 induced by contrast [5-7]. Although George et al. found that no remarkable difference existed in the 60 incidence of PEP between high and low-osmolality contrast, the role of contrast in pancreatic damage remains controversial [8]. Other underlying mechanisms include zymogen activation, genetic defects, 61 62 and flora disorder, however, these do not affect as large as mechanical damage or contrast damage to 63 pancreatic injury [9].

64 PEP is defined as the elevation of serum amylase level more than three times the upper limit of 65 normal within 24 hours, accompanied by typical clinical symptoms of pancreatitis, such as persistent pancreatitis-like abdominal pain [10]. There are many academic discussions on effective strategies to 66 67 prevent PEP, among them, pancreatic duct stenting and perioperative rectal nonsteroidal antiinflammatory drugs (NSAIDs) are widely accepted [11-13]. Additionally, aggressive hydration has been 68 69 also recommended by clinical researchers due to its promising preventive effect [14, 15]. The mechanism 70 of NSAIDs in preventing acute pancreatitis is related to their potent inhibitory effects on cyclooxygenase, 71 phospholipase A2, and interaction between neutrophils and endothelial cells, which activate 72 inflammatory cascade and lead to pancreatitis [16]. NSAIDs are an attractive option to prevent PEP 73 because of their affordability and easy patient management [17]. There is evidence that aggressive 74 perioperative hydration presents satisfactory efficacy in prevention of PEP [18-23]. Hydration improves 75 blood perfusion and stabilizes the pancreatic microcirculation by attenuating tissue acidification, 76 improving the prognosis of patients [24-27]. The mechanism of hydration is to protect the pancreatic 77 microcirculation and NSAIDs are aimed at suppressing the inflammatory response, however, whether hydration and rectal NSAIDs exhibit synergistic effects remains unclear [28-31]. The discussion on this 78 79 issue is still controversial [17, 32]. Therefore, we comprehensively reassess the efficacy of aggressive 80 hydration with rectal NSAIDs in comparison with rectal NSAIDs alone, providing evidence-based support for the prevention of PEP. 81

Methods 82

83 Search strategy

84 The study comprehensively searched ClinicalTrials, PubMed, CQVIP, Embase, Web of Science,

85 CNKI, Cochrane Library, and Wanfang Data, and searched for all relevant articles published before 86 September 2021. After several attempts, we chose to sacrifice a little precision to ensure the comprehensiveness of the search, while comparing several meta-analyses related to the content of this 87 study, and finally determined the search formula for this study. The search formula applied in PubMed is 88 89 as follows: (post-ercp [All Fields] AND ("pancreatitis" [MeSH Terms] OR "pancreatitis" [All Fields]) 90 AND ("prevention and control" [Subheading] OR ("prevention" [All Fields] AND"control" [All Fields]) OR"prevention and control" [All Fields] OR "prevention" [All Fields])) AND (randomized controlled 91

92 trial [Publication Type] OR randomized [Title/Abstract] OR placebo [Title/Abstract]).

93 Inclusion and exclusion criteria

94 We included all randomized controlled trials that contained a comparison of the efficacy of rectal 95 NSAIDs and rectal NSAIDs in combination with active fluid hydration for PEP prevention. Our inclusion 96 criteria included the following: a) RCTs that directly compared rectal NSAIDs combined with aggressive 97 hydration and rectal NSAIDs alone; b) our primary outcome was the rate of PEP and secondary outcomes 98 were the rate of severe and fatal cases of PEP (PEP was defined as serum amylase levels three times 99 higher than the upper limit of normal within 24 hours after ERCP and persistent pancreatitis-like 100 abdominal pain was observed). We excluded the following: a) RCTs in relation to combination of rectal 101 NSAIDs and pancreatic duct stents or RCTs that did not contain aggressive hydration; b) studies that did 102 not report complete experimental data or whose full text were not available; c) not RCTs.

103 Data extraction and management

104 We determined a data extraction table after several tests in advance. Two independent reviewers 105 extracted data from the included literature using the unified form. The main information extracted from the data extraction form included: lead author, year of publication, patient demographics (ie, country, 106 107 mean age, sex), sample size, intervention measure (ie, type of NSAIDs, NSAIDs dose, type of infusion 108 fluid, duration and volume of infusion), prevalence of PEP, mortality, and incidence of adverse effects 109 for each study. We also extracted relevant patient metrics and complication data that may be useful for 110 each experiment. In case of disagreement between two reviewers, the third reviewer negotiated and 111 resolved it. All reviewers agreed at the final results.

112 **Risk of bias assessment**

113 We evaluated the risk of bias in the relevant literature according to the seven aspects included in the Cochrane Handbook for Systematic Reviews of Interventions, including publication bias, time lag bias, 114 multiple publication bias, publication position bias, citation bias, language bias, and outcome reporting 115 116 bias. We also assessed the quality of the evidence based on GRADE ratings, which evaluate evidence 117 quality depending on study limitations, inconsistency of results, indirectness of evidence, imprecision of 118 results, and reporting bias. We classified the quality of evidence into four levels (high, moderate, low, or 119 very low).

120 **Statistical analysis**

121 Statistical analysis was performed by RevMan software (version 5.4). Data were collected with 122 dichotomous variables, and odds ratios (OR) and 95% confidence intervals (CI) were calculated. Statistical heterogeneity between studies was measured by I², and significant heterogeneity was indicated 123 when $I^2 > 50\%$. If the heterogeneity is not significant, a model or a random-effects model is generally 124 125 employed. Conversely, only the fixed-effects model is used while the heterogeneity is significant. We 126 performed statistical analysis of studies data using the random-effects model in this meta-analysis.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.02.22283014; this version posted December 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

127 Statistical significance was considered when the p-value < 0.05. Although the number of included

128 literatures was small, a sensitivity analysis was still performed. Sensitivity analysis showed that our

results were not affected by the heterogeneity of different literatures. 129

Results 130

Search results 131

1355 relevant articles were found from ClinicalTrials, PubMed, CQVIP, Embase, Web of Science, 132 CNKI, Cochrane Library, and Wanfang Data. We showed the complete retrieval process and screening 133 134 details in Figure 1. After multiple screening, literatures not included in the inclusion criteria or with 135 missing data were excluded. Finally, three RCTs with 1110 patients were included in this study and related results were presented in Figures 1-5 and Table 2. The PRISMA statement was followed in the 136 137 review process of our systematic review [33].

138 **Characteristics of trials**

We included 3 published studies of RCTs with 1110 patients. Of these three RCTs, two studies were 139 140 in the United States [34, 35] and one study was in Iran [17]. One was published in 2021, one in 2017, and one in 2016, all relatively novel studies within five years of each other and of good reference value. 141 142 The three included studies were full-text papers. With respect to hydration reagent, in one study, the 143 experimental group was injected with normal saline, while the control group did not [17]; and in the other 144 two studies [34, 35], Lactate Ringer solution was used in experimental group, while normal saline was used in control group. For NSAIDs, two trials were administered indomethacin [17, 34], and one trial 145 146 was administered indomethacin or diclofenac randomly [35]. All trials were administered rectally at a 147 dose of 100mg. More details such as patient information, interventions were presented in Table 1.

148 **Risk of bias in included studies**

149 Among three RCTs, one study [34] was single-blinded study. Two studies [17, 35] were double blinded studies. One study [35] did not provide enough information about incomplete outcome data 150 (attrition bias), while another two studies [17, 34] provided complete data in incomplete outcome data. 151 152 Funnel plots cannot assess true asymmetry when the sample size is less than 5 studies, so funnel plots 153 were not used to assess publication bias [36]. The assessment of publication bias of the included studies 154 was shown in Figure 2.

155 **Effects of interventions**

156 **Incidence of PEP**

157 Three studies [17, 34, 35] have reported this result involving 1110 patients. Since significant 158 heterogeneity was found with $I^2 > 50\%$, we used the random-effects model. The results showed that there 159 was no remarkable difference between patients receiving rectal NSAIDs alone and those receiving aggressive hydration in combination with NSAIDs in terms of incidence of PEP (OR, 0.43; 95% CI, 160 0.12-1.57; P=0.20). The forest plot was shown in Figure 3. 161

incidence of severe PEP 162

Two studies [34, 35] have reported this result including 909 patients. Although I^2 is less than 50%, the 163 164 random-effects model is still applicable. The results showed that there was no remarkable difference in 165 the incidence of severe PEP between rectal NSAIDs alone and aggressive hydration with rectal NSAIDs

166 (OR, 0.32; 95% CI, 0.10-1.08; P=0.07). The forest plots are shown in Figure 4.

167 Incidence of fatal PEP

Two studies [34, 35] have reported this result with 909 patients. We used the random-effects model
with I2<50%. The results revealed that there was also no remarkable difference in the incidence of fatal
cases between rectal NSAIDs alone and aggressive hydration combined with rectal NSAIDs (OR, 0.81;
95% CI, 0.28–2.36; P=0.70). The forest plots are shown in Figure 5.

172 Summary of findings and quality of evidence

We evaluated the quality of evidence for the role of aggressive hydration in preventing PEP based on GRADE ratings. Evidence level for evaluating PEP prevention in the group receiving aggressive hydration versus the standard group was moderate. Evidence level for evaluating severe PEP prevention in the group receiving aggressive hydration versus the standard group was very low. Evidence level for evaluating preventive effect on fatal PEP in the group receiving aggressive hydration versus the standard group was very low. The relevant study results and GRADE recommendations are in **Table 3**.

179 **Discussion**

We did a meta-analysis reviewing three RCTs with 1110 patients. The results showed that the combination of prophylactic rectal NSAIDs and perioperative hydration in experimental group did not decrease the incidence of PEP compared with rectal NSAIDs alone in standard group. Meanwhile, the combination therapy had no higher effect in preventing serious cases in comparison to NSAIDs individually, with not significantly different incidence of severe PEP and fatal cases.

185 As an essential diagnostic and therapeutic tools of pancreaticobiliary diseases, ERCP is widely performed but also presents some complications. Among of them, exhibiting a high incidence and 186 severity, PEP is receiving widespread attention. Although the identifying and managing the risk factors 187 188 associated with ERCP can minimize the associated complications, the prevalence of PEP continues to be high. The last decade has witnessed a tremendous advance in prevention strategies for PEP, application 189 of NSAIDs and placement of pancreatic duct stents have been broadly recognized in clinical practice for 190 avoiding this serious complication. In particular, rectal NSAIDs, which have dropped the development 191 192 of PEP significantly in 60% of cases. Moreover, a network meta-analysis including 29 studies showed 193 that rectal NSAIDs alone presented superior results in preventing PEP compared with pancreatic duct 194 stents alone (OR, 0.48; 95% CI, 0.26-0.87) [17]. Despite the use rectal NSAIDs, a high incidence of PEP 195 persists due to some contraindicated populations or intolerance to NSAIDs. Recently, perioperative 196 hydration has been recognized by several evidence-based guidance sourced form meta-analysis-level 197 evidence, often with astonishing benefits in terms of decreased risk and improved prognosis, offering a 198 new nonpharmacologic measure to reduce the morbidity and severity of PEP [18, 37]. A published metaanalysis including 10 RCTs with 2200 patients showed that aggressive intravenous infusion with Lactate 199 200 Ringer solution was superior to standard intravenous infusion in protecting high-risk groups from PEP 201 (OR, 0.40; 95% CI, 0.26-0.63; P < .0001) [34]. Furthermore, the positive role of aggressive hydration in decreasing the risk of developing PEP versus standard hydration was directly demonstrated in two 202 203 randomized controlled trials respectively conducted by Buxbaum et al. (0 [0%]t of 39 patients vs 4 [17%] 204 of 23 patients; 95% CI of difference 5.8, 35.9%; p=0.016) and Choi et al. (11 [4.3%] of 255 vs 25 [9.8%] 205 of 255 patients; relative risk [RR], 0.41; 95% CI, 0.20-0.86; P = .016) [35, 38]. These studies led to 206 international treatment guidelines recommending preoperative aggressive hydration to lower the risk of medRxiv preprint doi: https://doi.org/10.1101/2022.12.02.22283014; this version posted December 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

207 PEP [39, 40]. It has been suggested that combined aggressive hydration on the basis of rectal NSAIDs 208 might further diminish the occurrence of PEP. However, whether there is a collaborative facilitation 209 between rectal NSAIDs and aggressive hydration remains obscure.

Herein, we did a meta-analysis to assess the efficacy of additional aggressive hydration on patients 210 211 receiving rectal NSAIDs already. Our meta-analysis showed that patients receiving aggressive fluid 212 hydration (with Lactate Ringer solution or normal saline) plus rectal NSAIDs (100mg indomethacin or diclofenac) before or after ERCP procedure exhibited similar outcomes as patients who received rectal 213 214 NSAIDs alone (or combined with restricted hydration), that is, the incidence of PEP was not significantly 215 different (OR, 0.43; 95% CI, 0.12-1.57; P=0.20). A previous network meta-analysis presented analogous 216 results to our study that the combination of aggressive fluid hydration with Lactate Ringer solution and 217 rectal diclofenac 100 mg had no significant difference in preventing PEP over rectal diclofenac 100 mg alone (OR, 0.49; 95% CI, 0.26-0.94; low confidence). However, with regard to indomethacin, this meta-218 219 analysis concluded that the efficacy of the combination of standard hydration with normal saline and 220 rectal indomethacin 100 mg surpassed rectal indomethacin 100 mg alone in preventing PEP (OR, 0.04; 221 95% CI, 0.00-0.66; moderate confidence) [14]. Several meta-analysis-based evidences had shown that 222 the efficacy of indomethacin and diclofenac was similar [16, 39]. There was a high probability of false-223 positive results, on account of small sample sizes that included 1 RCT associated with rectal 224 indomethacin combined standard hydration trials in this network meta-analysis. On the other hand, our 225 results showed that no remarkable difference existed between patients receiving rectal NSAIDs alone and those receiving aggressive fluid hydration combined with rectal NSAIDs in incidence of severe PEP 226 227 (OR, 0.32; 95% CI, 0.10-1.08; P=0.07) and fatal cases (OR, 0.81; 95% CI, 0.28–2.36; P=0.70). Therefore, 228 the intravenous fluid hydration with 8-10 hours may be laborious and time-consuming for patients 229 received rectal NSAIDs already. However, intravenous fluid infusion is still the optimal choice for 230 patients with contraindications to NSAIDs due to its inexpensive and efficient nature.

231 Some shortcomings and limitations of our meta-analysis included the following: First, the number of includable literatures was not sufficient, and only three RCTs met the requirements. Secondly, sample 232 233 size of some included RCTs was excessively limited, which could not exclude the possibility of false-234 positive or false-negative results. Third, the different intervention measures in respective RCT studies 235 may increase the heterogeneity of our results. For instance, one RCT study [17] included in our meta-236 analysis compared the preventive effect of rectal indomethacin alone to the combination of intravenous 237 normal saline and rectal indomethacin; And another RCT study [35] compared the efficacy of rectal 238 indomethacin with intravenous Lactate Ringer solution to rectal indomethacin with intravenous normal 239 saline in preventing PEP. However, the sensitivity analysis had shown that our final results were not 240 affected by these different interventions.

241 In conclusion, aggressive perioperative hydration combined with rectal NSAID presented a modest effect in reducing the rate of PEP for patients received rectal NSAIDs already. Additionally, the 242 243 combination therapy of aggressive hydration and rectal NSAIDs showed poor efficacy in preventing 244 severe and fatal PEP. To some extent, aggressive hydration may be not necessary for patients who have 245 received rectal NSAIDs.

Statements and Declarations 246

There is no conflict of interest associated with this article. 247

Funding 248

This work was funded by Quality Engineering Project of Anhui Province (No.2020jyxm0898; 249

No.2020jyxm0910,No.2019kfkc334), Clinical research project of Anhui Medical University 250

251 (No.2020xkj176) and Soft health science research of Anhui province-Major project (No.2020WR01003).

References 252

- 253 1. Baiu I, Visser B: Endoscopic Retrograde Cholangiopancreatography. Jama 2018, 320:2050.
- 254 2. Kochar B, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, Khashab MA, Kalloo AN, 255 Singh VK: Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by 256 using randomized, controlled trials. Gastrointest Endosc 2015, 81:143-149.e149.
- 257 3. Chen JJ, Wang XM, Liu XQ, Li W, Dong M, Suo ZW, Ding P, Li Y: Risk factors for post-ERCP 258 pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. 259 Eur J Med Res 2014, 19:26.
- 260 4. Ding X, Zhang F, Wang Y: Risk factors for post-ERCP pancreatitis: A systematic review and 261 meta-analysis. Surgeon 2015, 13:218-229.
- 262 5. Obeidat AE, Mahfouz R, Monti G, Kozai L, Darweesh M, Mansour MM, Alqam A, Hernandez D: 263 Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: What We Already 264 Know. Cureus 2022, 14:e21773.
- Wong LL, Tsai HH: Prevention of post-ERCP pancreatitis. World J Gastrointest Pathophysiol 265 6. 266 2014, 5:1-10.
- 267 7. Freeman ML, Guda NM: Prevention of post-ERCP pancreatitis: a comprehensive review. 268 Gastrointest Endosc 2004. 59:845-864.
- 269 George S, Kulkarni AA, Stevens G, Forsmark CE, Draganov P: Role of osmolality of contrast 8. media in the development of post-ERCP pancreatitis: a metanalysis. Dig Dis Sci 2004, 49:503-270 271 508.
- 272 9. Tryliskyy Y, Bryce GJ: Post-ERCP pancreatitis: Pathophysiology, early identification and risk 273 stratification. Adv Clin Exp Med 2018, 27:149-154.
- 274 10. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N: 275 Endoscopic sphincterotomy complications and their management: an attempt at consensus. 276 Gastrointest Endosc 1991, 37:383-393.
- Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, 277 11. 278 Romagnuolo J, Elta GH, Sherman S, et al: A randomized trial of rectal indomethacin to prevent 279 post-ERCP pancreatitis. N Engl J Med 2012, 366:1414-1422.
- 280 12. Serrano JPR, de Moura DTH, Bernardo WM, Ribeiro IB, Franzini TP, de Moura ETH, Brunaldi VO, 281 Salesse MT, Sakai P, De Moura EGH: Nonsteroidal anti-inflammatory drugs versus placebo for 282 post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and 283 meta-analysis. Endosc Int Open 2019, 7:E477-e486.
- 284 13. Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J, 285 Kikuchi H: Pancreatic stents to prevent post-endoscopic retrograde 286 cholangiopancreatography pancreatitis: a meta-analysis. World J Metaanal 2019, 7:249-258. 287 Akshintala VS, Sperna Weiland CJ, Bhullar FA, Kamal A, Kanthasamy K, Kuo A, Tomasetti C, 14. 288 Gurakar M, Drenth JPH, Yadav D, et al: Non-steroidal anti-inflammatory drugs, intravenous 289 fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic

290		retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-
291		analysis. Lancet Gastroenterol Hepatol 2021, 6:733-742.
292	15.	Buxbaum J: Aggressive hydration and post-ERCP pancreatitis. Lancet Gastroenterol Hepatol
293		2021, 6 :686.
294	16.	Patai Á, Solymosi N, Mohácsi L, Patai Á V: Indomethacin and diclofenac in the prevention of
295		post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled
296		trials. Gastrointest Endosc 2017, 85:1144-1156.e1141.
297	17.	Hosseini M, Shalchiantabrizi P, Yektaroudy K, Dadgarmoghaddam M, Salari M: Prophylactic
298		Effect of Rectal Indomethacin Administration, with and without Intravenous Hydration, on
299		Development of Endoscopic Retrograde Cholangiopancreatography Pancreatitis Episodes: A
300		Randomized Clinical Trial. Arch Iran Med 2016, 19:538-543.
301	18.	Buxbaum J, Yan A, Yeh K, Lane C, Nguyen N, Laine L: Aggressive hydration with lactated
302		Ringer's solution reduces pancreatitis after endoscopic retrograde
303		cholangiopancreatography. Clin Gastroenterol Hepatol 2014, 12:303-307.e301.
304	19.	DiMagno MJ, Wamsteker EJ, Maratt J, Rivera MA, Spaete JP, Ballard DD, Elmunzer J, Saini SD:
305		Do larger periprocedural fluid volumes reduce the severity of post-endoscopic retrograde
306		cholangiopancreatography pancreatitis? Pancreas 2014, 43:642-647.
307	20.	Sagi SV, Schmidt S, Fogel E, Lehman GA, McHenry L, Sherman S, Watkins J, Coté GA: Association
308		of greater intravenous volume infusion with shorter hospitalization for patients with post-
309		ERCP pancreatitis. J Gastroenterol Hepatol 2014, 29:1316-1320.
310	21.	Shaygan-Nejad A, Masjedizadeh AR, Ghavidel A, Ghojazadeh M, Khoshbaten M: Aggressive
311		hydration with Lactated Ringer's solution as the prophylactic intervention for
312		postendoscopic retrograde cholangiopancreatography pancreatitis: A randomized controlled
313		double-blind clinical trial. J Res Med Sci 2015, 20:838-843.
314	22.	Grunwald D, Wadhwa V, Sawhney MS: Hemodynamic Variation and Intravenous Fluids
315		Administered During ERCP and the Association With Post-ERCP Pancreatitis. Pancreas 2016,
316		45: 293-297.
317	23.	Zhang ZF, Duan ZJ, Wang LX, Zhao G, Deng WG: Aggressive Hydration With Lactated Ringer
318		Solution in Prevention of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis:
319		A Meta-analysis of Randomized Controlled Trials. J Clin Gastroenterol 2017, 51:e17-e26.
320	24.	Rinderknecht H: Activation of pancreatic zymogens. Normal activation, premature
321		intrapancreatic activation, protective mechanisms against inappropriate activation. <i>Dig Dis</i>
322		<i>Sci</i> 1986, 31: 314-321.
323	25.	Kusterer K, Enghofer M, Zendler S, Blöchle C, Usadel KH: Microcirculatory changes in sodium
324		taurocholate-induced pancreatitis in rats. Am J Physiol 1991, 260 :G346-351.
325	26.	Strate T, Mann O, Kleinhans H, Rusani S, Schneider C, Yekebas E, Freitag M, Standl T, Bloechle
326	-	C. Izbicki JR: Microcirculatory function and tissue damage is improved after therapeutic
327		injection of bovine hemoglobin in severe acute rodent pancreatitis. <i>Pancreas</i> 2005. 30 :254-
328		259.
329	27.	Wu BU, Hwang JO, Gardner TH, Repas K, Delee R, Yu S, Smith B, Banks PA, Conwell DI : Lactated
330		Ringer's solution reduces systemic inflammation compared with saline in patients with acute
331		pancreatitis. Clin Gastroenterol Hepatol 2011. 9:710-717.e711.
332	28.	Mäkelä A. Kuusi T. Schröder T: Inhibition of serum phospholipase-A2 in acute pancreatitis by
333		pharmacological agents in vitro. Scand I Clin Lab Invest 1997 57:401-407
555		Finance of the second s

medRxiv preprint doi: https://doi.org/10.1101/2022.12.02.22283014; this version posted December 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

334 29. Cuthbertson CM, Christophi C: Disturbances of the microcirculation in acute pancreatitis. Br 335 J Sura 2006. 93:518-530.

336 30. Coté GA, Sagi SV, Schmidt SE, Lehman GA, McHenry L, Fogel E, Watkins J, Sherman S: Early 337 measures of hemoconcentration and inflammation are predictive of prolonged 338 hospitalization from post- endoscopic retrograde cholangiopancreatography pancreatitis. 339 Pancreas 2013, 42:850-854.

- 340 31. Gross V, Leser HG, Heinisch A, Schölmerich J: Inflammatory mediators and cytokines--new 341 aspects of the pathophysiology and assessment of severity of acute pancreatitis? 342 Hepatogastroenterology 1993, 40:522-530.
- 343 32. Hajalikhani M, Emami MH, Khodadoostan M, Shavakhi A, Rezaei M, Soluki R: Combination of 344 diclofenac and aggressive hydration for the prevention of post-ERCP pancreatitis. 345 Gastroenterology and hepatology from bed to bench 2018, **11**:319-324.
- 346 33. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred Reporting Items for Systematic Reviews 347 and Meta-Analyses: The PRISMA Statement. Plos Medicine 2009, 6.
- 348 Mok SRS, Ho HC, Shah P, Patel M, Gaughan JP, Elfant AB: Lactated Ringer's solution in 34. 349 combination with rectal indomethacin for prevention of post-ERCP pancreatitis and 350 readmission: a prospective randomized, double-blinded, placebo-controlled trial. 351 Gastrointestinal Endoscopy 2017, 85:1005-1013.
- 352 35. Sperna Weiland CJ, Smeets XJNM, Kievit W, Verdonk RC, Poen AC, Bhalla A, Venneman NG, 353 Witteman BJM, da Costa DW, van Eijck BC, et al: Aggressive fluid hydration plus non-steroidal 354 anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-355 endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-356 label, randomised, controlled trial. The Lancet Gastroenterology & Hepatology 2021, 6:350-357 358.
- 358 36. Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA: Enteral versus parenteral nutrition for 359 acute pancreatitis. Cochrane Database Syst Rev 2010, 2010: Cd002837.
- Smeets XJ, da Costa DW, Besselink MG, Bruno MJ, Fockens P, Mulder CJ, van der Hulst RW, 360 37. 361 Vleggaar FP, Timmer R, Drenth JP, van Geenen EJ: Systematic review: periprocedural hydration 362 in the prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther 2016, 44:541-553.
- 363 38. Choi JH, Kim HJ, Lee BU, Kim TH, Song IH: Vigorous Periprocedural Hydration With Lactated 364 **Ringer's** Solution Reduces the Risk of Pancreatitis After Retrograde 365 Cholangiopancreatography in Hospitalized Patients. Clin Gastroenterol Hepatol 2017, 15:86-366 92.e81.
- 367 39. Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, Bruining DH, Eloubeidi 368 MA, Fanelli RD, Faulx AL, Gurudu SR, et al: Adverse events associated with ERCP. Gastrointest 369 Endosc 2017, 85:32-47.
- 370 40. Dumonceau JM, Kapral C, Aabakken L, Papanikolaou IS, Tringali A, Vanbiervliet G, Beyna T, 371 Dinis-Ribeiro M, Hritz I, Mariani A, et al: ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2020, 52:127-149. 372
- 373
- 374
- 375
- 376
- 377

Study name	Weiland et al.	Mok et al.	Hosseini <i>et al</i> .
Location	USA	USA	Iran
Year	2021	2017	2016
Patient Age, vears	≤40 years old, 81 (AH)/67(SH)	Mean Age 63(AH)/62(SH)	Mean ± SD 47.91 ± 11.06(AH)/
	>40 years old, 307(AH)/358(SH)		51.20 ± 12.12 (SH)
a	Female,232(AH)/250(SH)	Female,23(AH)/33(SH)	Female,62(AH)/40(SH)
Sex	Male,156(AH)/175(SH)	Male,25(AH)/15(SH)	Male,39(AH)/60(SH)
Previous pancreatitis	13(AH)/13(SH)	0(AH)/1(SH)	-
Pancreatic duct stent placement	58(AH)/73((SH)	10(AH)/12(SH)	-
Difficult cannulation	113(AH)/123(SH)	6(AH)/8(SH)	-
Trainee involvement	33(AH)/34(SH)	48(AH)/48(SH)	-
Study design	RCT n=813(388AH/425SH)	RCT n=96(48AH/48SH)	RCT n=201(101AH/100SH)
	AH: Receive rectal NSAIDs 100mg	AH: Received preoperative	AH: rectal
	within 30 min before or after ERCP	rectal injection of	indomethacin and
	procedure and 20 mL/kg of Lactate	indomethacin 100 mg and	intravenous normal
	Ringer solution intravenously	preoperative intravenous	saline.
Intervention	within 60 minutes as the beginning	1000 ml of Lactate Ringer	SH: 100 mg of
(AH/SH)	of the procedure, followed by 3	solution.	Indomethacin rectally
	mL/kg every hour for 8 hours.	SH: Received intraoperative	two hours before the
	SH: Receive rectal NSAID 100 mg	intravenous normal saline and	ERCP procedure.
	alone and restrict intravenous	preoperative rectal injection	
	infusion of normal saline.	of indomethacin 100 mg.	

378 Table 1 Characteristics of included studies



397 Table 2 Assessment of quality of evidence.

Outcomes	Assumed risk NSAIDs alone	mparative risks*(95%CI) Corresponding risk Fluid hydration plus NSAIDs	Relative effect (95% CI)	No of Participants(studies)	Quality of t evidence (GRADE
PEP	Study populatio	n	OR 0.43	1110(3 studies)	@ # # #
	98 per 100	45 per 1000 (13 to 145)	(0.12 to	()	moderate
	Moderate	/	_ 1.57)		
	110 per 1000	50 per 1000 (15 to 163)	-		
Severe	Study populatio	n	OR 0.32	909 (2studies)	⊕⊖⊖⊕
PEP	23 per 1000	8 per 1000 (2 to 25)	(0.10 to 1.08)		very low
	Moderate				
	22 per 1000	7 per 1000 (2 to 24)	-		
Death	Study populatio	n	OR 0.81	909 (2studies)	⊕⊖⊖⊕
	17 per 1000	14 per 1000 (5 to 39)	(0.28 to 2.36)		very low
	Moderate		_		
	28 per 1000	22 man 1000			
CI = Confidence	e interval, OR = Odd	(8 to 64) (8 ratio, PEP = post -ERCP pancreat	titis.		
CI = Confidence	e interval, OR = Odd	(8 to 64) ls ratio, PEP = post -ERCP pancreal	titis.		
CI = Confidence	e interval, OR = Odd	(8 to 64) ls ratio, PEP = post -ERCP pancreal	titis.		
CI = Confidence	e interval, OR = Odd	(8 to 64) Is ratio, PEP = post -ERCP pancrea	titis.		
CI = Confidence	e interval, OR = Odd	(8 to 64) ls ratio, PEP = post -ERCP pancreal	titis.		
CI = Confidence	e interval, OR = Odd	(8 to 64) Is ratio, PEP = post -ERCP pancreal	titis.		
CI = Confidence	e interval, OR = Odd	(8 to 64) ls ratio, PEP = post -ERCP pancreal	titis.		

Table 3 Statistical results of included studies

	No. of	AH/SH	Relative risk	Р	
Groups	Studies				
	(References)		(95%C1)		
Pseudocyst	1(27)	1(48)/0(48)	-	1.00	
Exocrine insufficiency	1(28)	0(388)/2(425)	0.40 (0.02–7.69)	0.25	
Endocrine insufficiency	1(28)	4(388)/3(425)	1.70 (0.44–6.66)	0.49	
Duration of hospital stay, nights	1(28)	1(388)/1(425)	-	0.77	
ERCP-related complications	1(28)	16(388)/21(425)	0.90 (0.62–1.31)	0.62	
Cholangitis	1(28)	2(388)/6(425)	-	0.44	
Bleeding	2(27,28)	10(436)/12(473)	-	0.53	
Perforation	1(28)	5(388)/4(425)	-	0.49	
Hydration-related complications	1(28)	8(388)/9(425)	0.99 (0.59–1.64)	1.00	
Pulmonary oedema	2(27,28)	3(436)/5(473)	-	0.80	
Peripheral oedema	1(28)	6(388)/3(425)	-	0.22	
Cardiac insufficiency	1(28)	0(388)/3(425)	-	0.25	
Hypernatraemia	1(28)	1(388)/1(425)	-	$1 \cdot 00$	
ICU admission after ERCP	1(28)	2(388)/6(425)	0.37 (0.07–1.80)	0.22	
Mortality during 180-day follow- up	1(28)	11(388)/12(425)	1.00 (0.45–2.25)	1.00	
Cholangitis during 180-day	1(28)	5(388)/8(425)	0.68 (0.23–2.08)	0.50	
Renal Failure	1(27)	1(48)/1(48)	-	1.00	
Anaphylaxis	1(27)	0(48)/0(48)	-	1.00	
Readmission	1(27)	1(48)/2(48)	-	-	









Figure 4 Forest plot of incidence of severe PEP between rectal NSAIDs alone and aggressive hydration

combined with rectal NSAIDs.



573

Figure 5 Forest plot of incidence of fatal PEP between rectal NSAIDs alone and aggressive hydration 574

combined with rectal NSAIDs. 575